Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Prostate Cancer

Free Subscription Articles published in Int J Radiat Oncol Biol Phys Retrieve available abstracts of 221 articles: HTML format

Single Articles

July 2020
1. MITIN T, Choudhury A
   Flattening the Curve of Prostate Cancer Progression: Accurate Detection and Safe Ablation.
   Int J Radiat Oncol Biol Phys. 2020;107:609-612.
   PubMed    
   
   
   June 2020
2. ROY S, Grimes S, Eapen L, Spratt DE, et al
   Impact of Sequencing of Androgen Suppression and Radiotherapy on Testosterone Recovery in Localized Prostate Cancer.
   Int J Radiat Oncol Biol Phys. 2020 Jun 18. pii: S0360-3016(20)31258.
   PubMed     Abstract available
   
   
   
3. PARIKH NR, Kishan AU, Kane N, Diaz-Perez S, et al
   Phase I Trial of Stereotactic Body Radiotherapy Neoadjuvant to Radical Prostatectomy for Patients with High-Risk Prostate Cancer.
   Int J Radiat Oncol Biol Phys. 2020 Jun 17. pii: S0360-3016(20)31251.
   PubMed     Abstract available
   
   
   
4. PARIKH NR, Chang EM, Nickols NG, Rettig MB, et al
   Cost-effectiveness of metastasis-directed therapy in oligorecurrent hormone-sensitive prostate cancer.
   Int J Radiat Oncol Biol Phys. 2020 Jun 13. pii: S0360-3016(20)31250.
   PubMed     Abstract available
   
   
   
5. JACCARD M, Zilli T, Dubouloz A, Escude L, et al
   Urethra-sparing stereotactic body radiotherapy for prostate cancer: quality assuranceof a randomized phase II trial.
   Int J Radiat Oncol Biol Phys. 2020 Jun 11. pii: S0360-3016(20)31242.
   PubMed     Abstract available
   
   
   
6. KOLLMEIER MA, McBride S, Varghese M, Debonis D, et al
   Low dose rate brachytherapy combined with ultra-hypofractionated radiation therapy for clinically localized, intermediate-risk prostate cancer: Results from a prospective trial.
   Int J Radiat Oncol Biol Phys. 2020 Jun 4. pii: S0360-3016(20)31189.
   PubMed    
   
   
   
7. 
   Erratum to: Liu W, Zukotynski K, Emmett L, Chung HT, Chung P, Wolfson R, Rachinsky I, Kapoor A, Metser U, Loblaw A, Morton G, Sexton T, Lock M, Helou J, Berlin A, Boylan C, Archer S, Pond GR, Bauman G. A Prospective Study of 18F-DCFPyL PSMA PET/CT Res
   Int J Radiat Oncol Biol Phys. 2020;107:390.
   PubMed    
   
   
   April 2020
8. QIN H, Zhang V, Bok RA, Santos RD, et al
   Simultaneous metabolic and perfusion imaging using hyperpolarized (13)C MRI can evaluate early and dose-dependent responses to radiotherapy in a prostate cancer mouse model.
   Int J Radiat Oncol Biol Phys. 2020 Apr 24. pii: S0360-3016(20)31042.
   PubMed     Abstract available
   
   
   March 2020
9. KEALL P, Nguyen DT, O'Brien R, Hewson E, et al
   Real-Time Image-Guided Ablative Prostate Cancer Radiation Therapy: Results from the TROG 15.01 SPARK Trial.
   Int J Radiat Oncol Biol Phys. 2020 Mar 29. pii: S0360-3016(20)30937.
   PubMed     Abstract available
   
   
   
10. DESS RT
    Treatment Intensification in High-Risk Prostate Cancer: Lessons From the TROG 03.04 RADAR Trial.
    Int J Radiat Oncol Biol Phys. 2020;106:703-705.
    PubMed    
    
    
    
11. JOSEPH D, Denham JW, Steigler A, Lamb DS, et al
    Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial.
    Int J Radiat Oncol Biol Phys. 2020;106:693-702.
    PubMed     Abstract available
    
    
    
12. ACHARD V, Zilli T
    In Regard to Qi et al.
    Int J Radiat Oncol Biol Phys. 2020;106:887-888.
    PubMed    
    
    
    
13. KOONTZ BF, Pra AD
    Shifting the Curtain-Can We Make Sense of the Whole Pelvis Controversy?
    Int J Radiat Oncol Biol Phys. 2020;106:534-536.
    PubMed    
    
    
    
14. HAGAN M, Kapoor R, Michalski J, Sandler H, et al
    VA-Radiation Oncology Quality Surveillance Program.
    Int J Radiat Oncol Biol Phys. 2020;106:639-647.
    PubMed     Abstract available
    
    
    
15. SAMPATH S, Frankel P, Vecchio BD, Ruel N, et al
    Stereotactic Body Radiation Therapy to the Prostate Bed: Results of a Phase 1 Dose-Escalation Trial.
    Int J Radiat Oncol Biol Phys. 2020;106:537-545.
    PubMed     Abstract available
    
    
    
16. VITZTHUM LK, Park H, Zakeri K, Heide ES, et al
    Risk of Pelvic Fracture With Radiation Therapy in Older Patients.
    Int J Radiat Oncol Biol Phys. 2020;106:485-492.
    PubMed     Abstract available
    
    
    February 2020
17. SUN L, Smith W, Kirkby C
    Variation in Inter-institutional Plan Quality When Adopting A Hypofractionated Protocol for Prostate Cancer External Beam Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2020 Feb 26. pii: S0360-3016(20)30252.
    PubMed     Abstract available
    
    
    
18. AKSNESSAETHER BY, Myklebust TA, Solberg A, Klepp OH, et al
    "Second cancers in patients with locally advanced prostate cancer randomized to lifelong endocrine treatment with or without radical radiotherapy. Long term follow- up of the Scandinavian Prostate Cancer Group-7 trial."
    Int J Radiat Oncol Biol Phys. 2020 Feb 26. pii: S0360-3016(20)30253.
    PubMed    
    
    
    
19. POLLACK A, Chinea FM, Bossart E, Kwon D, et al
    PHASE i TRIAL OF MRI-GUIDED Prostate Cancer Lattice Extreme Ablative Dose (LEAD) BOOST Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2020 Feb 18. pii: S0360-3016(20)30218.
    PubMed     Abstract available
    
    
    
20. SCARSBROOK AF, Bottomley D, Teoh EJ, Bradley KM, et al
    Impact of (18)F-fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: results from the FALCON trial.
    Int J Radiat Oncol Biol Phys. 2020 Feb 14. pii: S0360-3016(20)30203.
    PubMed     Abstract available
    
    
    
21. DINH TT, Lee HJ Jr, Macomber MW, Apisarnthanarax S, et al
    Rectal Hydrogel Spacer Improves Late Gastrointestinal Toxicity Compared To Rectal Balloon Immobilization After Proton Beam Radiotherapy For Localized Prostate Cancer: A Retrospective Observational Study.
    Int J Radiat Oncol Biol Phys. 2020 Feb 5. pii: S0360-3016(20)30152.
    PubMed     Abstract available
    
    
    
22. LIN J, Den RB, Greenspan J, Showalter TN, et al
    Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Feb 3. pii: S0360-3016(19)34522.
    PubMed     Abstract available
    
    
    
23. TENDULKAR RD, Mian OY
    Yes, Nodal Recurrence of Prostate Cancer is Potentially Curable.
    Int J Radiat Oncol Biol Phys. 2020;106:238.
    PubMed    
    
    
    
24. BALLAS LK
    Nodal Recurrence From Prostate Adenocarcinoma: Curable.
    Int J Radiat Oncol Biol Phys. 2020;106:238-239.
    PubMed    
    
    
    
25. RODRIGUEZ-LOPEZ JL, Beriwal S
    Nodal Recurrence From Prostate Adenocarcinoma: Curable or Incurable?
    Int J Radiat Oncol Biol Phys. 2020;106:236-237.
    PubMed    
    
    
    
26. CORNELL M, Kaderka R, Hild SJ, Ray XJ, et al
    Noninferiority Study of Automated Knowledge-Based Planning Versus Human-Driven Optimization Across Multiple Disease Sites.
    Int J Radiat Oncol Biol Phys. 2020;106:430-439.
    PubMed     Abstract available
    
    
    
27. FULLER D, Wurzer J, Shirazi R, Bridge S, et al
    Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT.
    Int J Radiat Oncol Biol Phys. 2020;106:291-299.
    PubMed     Abstract available
    
    
    January 2020
28. VAN SON MJ, Peters M, Moerland MA, Lagendijk JJW, et al
    MRI-guided ultrafocal salvage high-dose-rate brachytherapy for localized radiorecurrent prostate cancer: updated results of 50 patients.
    Int J Radiat Oncol Biol Phys. 2020 Jan 29. pii: S0360-3016(20)30129.
    PubMed     Abstract available
    
    
    
29. RASMUSSON E, Gunnlaugsson A, Wieslander E, Hoglund P, et al
    Erectile dysfunction and absorbed dose to penile base structures in a randomized trial comparing ultra-hypofractionated and conventionally fractionated radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jan 28. pii: S0360-3016(20)30128.
    PubMed     Abstract available
    
    
    
30. VOGELIUS IR, Bentzen SM
    Diminishing returns from ultra-hypofractionated radiation therapy for prostate cancer.
    Int J Radiat Oncol Biol Phys. 2020 Jan 24. pii: S0360-3016(20)30069.
    PubMed     Abstract available
    
    
    
31. KANG J, Thompson RF, Fuller CD, Camphausen KA, et al
    In Regard to Wallner et al.
    Int J Radiat Oncol Biol Phys. 2020;106:217-218.
    PubMed    
    
    
    
32. MARPLES B, Wilson GD
    Predicting Outcome using Genomic-Based Liquid Biomarkers.
    Int J Radiat Oncol Biol Phys. 2020;106:1-4.
    PubMed    
    
    
    
33. NOSRATI R, Wronski M, Tseng CL, Chung H, et al
    Postimplant Dosimetry of Permanent Prostate Brachytherapy: Comparison of MRI-Only and CT-MRI Fusion-Based Workflows.
    Int J Radiat Oncol Biol Phys. 2020;106:206-215.
    PubMed     Abstract available
    
    
    
34. ONG WL, Foroudi F, Milne RL, Millar JL, et al
    Variation in the Use of Single- Versus Multifraction Palliative Radiation Therapy for Bone Metastases in Australia.
    Int J Radiat Oncol Biol Phys. 2020;106:61-66.
    PubMed     Abstract available
    
    
    December 2019
35. MURRAY JR, Tree AC, Alexander E, Sohaib A, et al
    Standard and hypofractionated dose escalation to intraprostatic tumour nodules in localised prostate cancer: efficacy and toxicity in the DELINEATE trial.
    Int J Radiat Oncol Biol Phys. 2019 Dec 5. pii: S0360-3016(19)34461.
    PubMed     Abstract available
    
    
    
36. HENRY A
    Using Multiparametric Magnetic Resonance Imaging to Shift Prostate Cancer Diagnosis Toward Clinically Significant Disease and Minimize Overdiagnosis (and Overtreatment).
    Int J Radiat Oncol Biol Phys. 2019;105:915-917.
    PubMed    
    
    
    
37. LARGENT A, Barateau A, Nunes JC, Mylona E, et al
    Comparison of Deep Learning-Based and Patch-Based Methods for Pseudo-CT Generation in MRI-Based Prostate Dose Planning.
    Int J Radiat Oncol Biol Phys. 2019;105:1137-1150.
    PubMed     Abstract available
    
    
    November 2019
38. AKSNESSAETHER BY, Myklebust TA, Solberg A, Klepp OH, et al
    Second cancers in patients with locally advanced prostate cancer randomized to lifelong endocrine treatment with or without radical radiotherapy. Long term follow- up of the Scandinavian Prostate Cancer Group-7 trial.
    Int J Radiat Oncol Biol Phys. 2019 Nov 28. pii: S0360-3016(19)34066.
    PubMed     Abstract available
    
    
    
39. THORNQVIST S 2ND, Abal B, Ovrelid KS, Engeseth GM, et al
    Plan selection in proton therapy of locally advanced prostate cancer with simultaneous treatment of multiple targets.
    Int J Radiat Oncol Biol Phys. 2019 Nov 20. pii: S0360-3016(19)34005.
    PubMed     Abstract available
    
    
    
40. QUINN TJ, Hamstra D
    Hypofractionation in Prostate Cancer Using Proton Beam.
    Int J Radiat Oncol Biol Phys. 2019;105:723-726.
    PubMed    
    
    
    
41. LIU W, Zukotynski K, Emmett L, Chung HT, et al
    A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2019 Nov 12. pii: S0360-3016(19)33971.
    PubMed     Abstract available
    
    
    
42. MITIN T, Henry A, Choudhury A, Chen RC, et al
    SBRT for Localized Prostate Cancer: Is it Ready for Take-Off?
    Int J Radiat Oncol Biol Phys. 2019;105:618-620.
    PubMed    
    
    
    
43. JIANG NY, Dang AT, Yuan Y, Chu FI, et al
    Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2019;105:628-636.
    PubMed     Abstract available
    
    
    
44. BIRD D, Henry AM, Sebag-Montefiore D, Buckley DL, et al
    A Systematic Review of the Clinical Implementation of Pelvic Magnetic Resonance Imaging-Only Planning for External Beam Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2019;105:479-492.
    PubMed     Abstract available
    
    
    October 2019
45. QI X, Gao XS, Li HZ, Qin SB, et al
    Toxicity and Biochemical Outcomes of Dose-Intensified Post-Operative Radiation Therapy for Prostate Cancer: Results of a Randomized Phase III Trial.
    Int J Radiat Oncol Biol Phys. 2019 Oct 25. pii: S0360-3016(19)33948.
    PubMed     Abstract available
    
    
    
46. THARMALINGAM H, Tsang Y, Choudhury A, Alonzi R, et al
    External beam radiotherapy (EBRT) and high-dose rate (HDR) brachytherapy for intermediate and high-risk prostate cancer: the impact of EBRT volume.
    Int J Radiat Oncol Biol Phys. 2019 Oct 11. pii: S0360-3016(19)33877.
    PubMed     Abstract available
    
    
    
47. PASQUIER D, Peiffert D, Nickers P, Maingon P, et al
    A multicentre phase II study of hypofractionated stereostatic boost in intermediate risk prostate carcinoma: a 5-year analysis of the CKNO-PRO trial.
    Int J Radiat Oncol Biol Phys. 2019 Oct 8. pii: S0360-3016(19)33863.
    PubMed     Abstract available
    
    
    
48. DE VRIES KC, Wortel RC, Hoop EO, Heemsbergen WD, et al
    Hyprofractionated versus conventionally fractionated radiotherapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multi-centre, open-label, phase 3 HYPRO trial.
    Int J Radiat Oncol Biol Phys. 2019 Oct 5. pii: S0360-3016(19)33827.
    PubMed     Abstract available
    
    
    August 2019
49. BRUYNZEEL AME, Tetar SU, Oei SS, Senan S, et al
    A prospective single-arm phase II study of stereotactic magnetic-resonance-guided adaptive radiotherapy for prostate cancer: Early toxicity results.
    Int J Radiat Oncol Biol Phys. 2019 Aug 13. pii: S0360-3016(19)33640.
    PubMed     Abstract available
    
    
    
50. DEEK MP, Yu C, Phillips R, Song DY, et al
    Radiotherapy In The Definitive Management Of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.
    Int J Radiat Oncol Biol Phys. 2019 Aug 13. pii: S0360-3016(19)33641.
    PubMed     Abstract available
    
    
    
51. MOON DH, Chen RC
    Partial Prostate Cancer Treatment for Aggressive Disease-Common Practice.
    Int J Radiat Oncol Biol Phys. 2019;104:1035-1037.
    PubMed    
    
    
    
52. MARVASO G, Ciardo D, Gandini S, Riva G, et al
    Comparison of outcomes and toxicity between extreme and moderate radiotherapy hypofractionation in localized prostate cancer: a propensity score analysis.
    Int J Radiat Oncol Biol Phys. 2019 Aug 1. pii: S0360-3016(19)33531.
    PubMed     Abstract available
    
    
    
53. JULIET VAN SON M, Peters M, Moerland MA, van der Voort van Zyp JRN, et al
    In Reply to David and Kamrava.
    Int J Radiat Oncol Biol Phys. 2019;104:1183-1184.
    PubMed    
    
    
    
54. DAVID J, Kamrava M
    In Regard to Peters et al.
    Int J Radiat Oncol Biol Phys. 2019;104:1182-1183.
    PubMed    
    
    
    
55. MORTON GC, Hoskin PJ
    Single Fraction High-Dose-Rate Brachytherapy: Too Good to Be True?
    Int J Radiat Oncol Biol Phys. 2019;104:1054-1056.
    PubMed    
    
    
    
56. HAWKEN SR, Spratt DE, Qi J, Linsell SM, et al
    Utilization of Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy.
    Int J Radiat Oncol Biol Phys. 2019;104:1030-1034.
    PubMed     Abstract available
    
    
    July 2019
57. TAPROGGE J, Murray I, Gear J, Chittenden SJ, et al
    Title: Compartmental model for (223)Ra-Dichloride in patients with metastatic bone disease from castration-resistant prostate cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jul 23. pii: S0360-3016(19)33505.
    PubMed     Abstract available
    
    
    
58. PASQUIER D, Martinage G, Janoray G, Rojas DP, et al
    Salvage stereotactic body radiotherapy for local prostate cancer recurrence after radiotherapy: a retrospective multicentre study of the GETUG.
    Int J Radiat Oncol Biol Phys. 2019 Jul 22. pii: S0360-3016(19)33494.
    PubMed     Abstract available
    
    
    
59. SPRATT DE, Michalski JM
    Long-Term Benefits of Dose-Escalation in Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019;104:798-800.
    PubMed    
    
    
    
60. LIU C, Gardner SJ, Wen N, Elshaikh MA, et al
    Automatic Segmentation of the Prostate on CT Images Using Deep Neural Networks (DNN).
    Int J Radiat Oncol Biol Phys. 2019;104:924-932.
    PubMed     Abstract available
    
    
    
61. PASALIC D, Kuban DA, Allen PK, Tang C, et al
    Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2019;104:790-797.
    PubMed     Abstract available
    
    
    
62. MURALIDHAR V, Zhang J, Wang Q, Mahal BA, et al
    Genomic validation of three-tiered clinical sub-classification of high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jul 1. pii: S0360-3016(19)33398.
    PubMed     Abstract available
    
    
    June 2019
63. OSMAN SO, Leijenaar RT, Cole AJ, Lyons CA, et al
    CT-based Radiomics for Risk Stratification in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jun 26. pii: S0360-3016(19)33392.
    PubMed     Abstract available
    
    
    
64. YOSHIDA S, Takahara T, Arita Y, Ishii C, et al
    Progressive site-directed therapy for castration-resistant prostate cancer: localization of the progressive site as a prognostic factor.
    Int J Radiat Oncol Biol Phys. 2019 Jun 12. pii: S0360-3016(19)30837.
    PubMed     Abstract available
    
    
    
65. LEUFGENS F, Berneking V, Vogeli TA, Kirschner-Hermanns R, et al
    Quality of life changes >10 years following postoperative radiotherapy after radical prostatectomy for prostate cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jun 12. pii: S0360-3016(19)30829.
    PubMed     Abstract available
    
    
    
66. GREWAL AS, Schonewolf C, Min EJ, Chao HH, et al
    Four-year outcomes from a prospective phase II clinical trial of moderately hypofractionated proton therapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys. 2019 Jun 11. pii: S0360-3016(19)30827.
    PubMed     Abstract available
    
    
    
67. JACKSON IL, Pavlovic R, Alexander AA, Connors CQ, et al
    BIO 300, a nanosuspension of genistein, mitigates radiation-induced erectile dysfunction and sensitizes human prostate cancer xenografts to radiation therapy.
    Int J Radiat Oncol Biol Phys. 2019 Jun 5. pii: S0360-3016(19)30816.
    PubMed     Abstract available
    
    
    
68. SANDLER HM
    Responding to Information From Novel Positron Emission Tomography Imaging in Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019;104:263-264.
    PubMed    
    
    
    
69. MENZEL P, Chang A
    Prostate-Specific Membrane Antigen Positron Emission Tomography-Identified Para-aortic Prostate Cancer Recurrence After Surgery and Salvage Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2019;104:261-262.
    PubMed    
    
    
    
70. SPRATT DE
    What Are We Even Looking At?
    Int J Radiat Oncol Biol Phys. 2019;104:264-265.
    PubMed    
    
    
    
71. LI YR, Roach M 3rd
    Stampede to Cure.
    Int J Radiat Oncol Biol Phys. 2019;104:264.
    PubMed    
    
    
    
72. MITO JK, Mitra D, Barysauskas CM, Marino-Enriquez A, et al
    A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas.
    Int J Radiat Oncol Biol Phys. 2019;104:425-435.
    PubMed     Abstract available
    
    
    May 2019
73. YUAN Y, Aghdam N, King C, Fuller D, et al
    Testosterone Levels and Sexual Quality of Life Following Stereotactic Body Radiotherapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials.
    Int J Radiat Oncol Biol Phys. 2019 May 17. pii: S0360-3016(19)30727.
    PubMed     Abstract available
    
    
    
74. FERNANDES CD, Simoes R, Ghobadi G, Heijmink SW, et al
    Multi-parametric MRI tumor probability model for the detection of locally recurrent prostate cancer after radiotherapy: pathological validation and comparison with manual tumor delineations.
    Int J Radiat Oncol Biol Phys. 2019 May 11. pii: S0360-3016(19)30703.
    PubMed     Abstract available
    
    
    
75. CHOUDHURY A, Chen RC, Henry A, Mistry H, et al
    STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?
    Int J Radiat Oncol Biol Phys. 2019;104:33-35.
    PubMed    
    
    
    
76. 
    Erratum to: Wilkins AC, Gusterson B, Szijgyarto Z, et al. Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2018;101:309-315
    Int J Radiat Oncol Biol Phys. 2019;104:226.
    PubMed    
    
    
    
77. BRYANT AK, Rose BS
    In Reply to Hurmuz and Ozyigit.
    Int J Radiat Oncol Biol Phys. 2019;104:225.
    PubMed    
    
    
    
78. HURMUZ P, Ozyigit G
    In Regard to Bryant et al.
    Int J Radiat Oncol Biol Phys. 2019;104:224-225.
    PubMed    
    
    
    
79. BALLAS LK, Luo C, Chung E, Kishan AU, et al
    Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy.
    Int J Radiat Oncol Biol Phys. 2019;104:50-60.
    PubMed     Abstract available
    
    
    April 2019
80. ALAYED Y, Loblaw A, Chu W, Al-Hanaqta M, et al
    Stereotactic Body Radiotherapy Boost for Intermediate Risk Prostate Cancer: A Phase 1 Dose Escalation Study.
    Int J Radiat Oncol Biol Phys. 2019 Apr 16. pii: S0360-3016(19)30624.
    PubMed     Abstract available
    
    
    
81. HALLEMEIER CL, Zhang P, Pisansky TM, Hanks GE, et al
    Prostate-specific antigen after neoadjuvant androgen suppression in prostate cancer patients receiving short-term androgen suppression and external beam radiotherapy: pooled analysis of four NRG Oncology RTOG randomized clinical trials.
    Int J Radiat Oncol Biol Phys. 2019 Apr 5. pii: S0360-3016(19)30610.
    PubMed     Abstract available
    
    
    
82. JACKSON WC, Silva J, Hartman HE, Dess RT, et al
    Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.
    Int J Radiat Oncol Biol Phys. 2019 Apr 5. pii: S0360-3016(19)30612.
    PubMed     Abstract available
    
    
    
83. SONI PD
    Selection Bias in Population Registry-Based Comparative Effectiveness Research.
    Int J Radiat Oncol Biol Phys. 2019;103:1058-1060.
    PubMed    
    
    
    March 2019
84. PETERS M, van Son MJ, Moerland MA, Kerkmeijer LGW, et al
    MRI-guided ultrafocal HDR-brachytherapy for localised prostate cancer: median 4 year results of a feasibility study.
    Int J Radiat Oncol Biol Phys. 2019 Mar 26. pii: S0360-3016(19)30399.
    PubMed     Abstract available
    
    
    
85. MCCARTHY M, Francis R, Tang C, Watts J, et al
    A multicentre prospective clinical trial of (68)Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: Oligometastatic rate and distribution, compared to standard imaging.
    Int J Radiat Oncol Biol Phys. 2019 Mar 16. pii: S0360-3016(19)30370.
    PubMed     Abstract available
    
    
    
86. CICCHETTI A, Fiorino C, Rancati T, Valdagni R, et al
    In Reply to Loganadane et al.
    Int J Radiat Oncol Biol Phys. 2019;103:777-778.
    PubMed    
    
    
    
87. LOGANADANE G, Coraggio G, Belkacemi Y
    In Regard to Cicchetti et al.
    Int J Radiat Oncol Biol Phys. 2019;103:776-777.
    PubMed    
    
    
    
88. PARIKH RR
    Aggressive Focal Therapy.
    Int J Radiat Oncol Biol Phys. 2019;103:546.
    PubMed    
    
    
    February 2019
89. D'AGOSTINO GR, di Brina L, Mancosu P, Franzese C, et al
    Re-Irradiation of Locally Recurrent Prostate Cancer with Volumetric Modulated Arc Therapy (Vmat).
    Int J Radiat Oncol Biol Phys. 2019 Feb 27. pii: S0360-3016(19)30285.
    PubMed     Abstract available
    
    
    
90. SIDDIQUI ZA, Gustafson GS, Ye H, Martinez AA, et al
    5-Year Outcomes of a Single Institution Prospective Trial of 19 Gy Single-Fraction HDR Brachytherapy for Low- and Intermediate-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Feb 13. pii: S0360-3016(19)30205.
    PubMed     Abstract available
    
    
    
91. POTTERS L, Rana Z, Lee L, Cox BW, et al
    Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase I/II trial for Patients with Low and Intermediate-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Feb 2. pii: S0360-3016(19)30183.
    PubMed     Abstract available
    
    
    
92. ABU-GHEIDA I, Reddy CA, Kotecha R, Weller MA, et al
    Ten-year outcomes of moderately hypofractionated (70 Gy in 28 fractions) intensity modulated radiotherapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys. 2019 Feb 2. pii: S0360-3016(19)30182.
    PubMed     Abstract available
    
    
    
93. MITIN T, Nguyen PL
    Postoperative Radiation Therapy in Localized Prostate Cancer: When, How Much, and How Fast?
    Int J Radiat Oncol Biol Phys. 2019;103:289-292.
    PubMed    
    
    
    
94. MYLONA E, Acosta O, Lizee T, Lafond C, et al
    Voxel-based analysis for identification of urethro-vesical subregions predicting urinary toxicity after prostate cancer radiotherapy.
    Int J Radiat Oncol Biol Phys. 2019 Feb 1. pii: S0360-3016(19)30179.
    PubMed     Abstract available
    
    
    
95. YU JB, Beck TF, Anscher MS, Baschnagel AM, et al
    The ASTRO Research Portfolio: Where Do We Go From Here?
    Int J Radiat Oncol Biol Phys. 2019;103:308-309.
    PubMed    
    
    
    
96. LARGENT A, Barateau A, Nunes JC, Lafond C, et al
    Pseudo-CT Generation for MRI-Only Radiation Therapy Treatment Planning: Comparison Among Patch-Based, Atlas-Based, and Bulk Density Methods.
    Int J Radiat Oncol Biol Phys. 2019;103:479-490.
    PubMed     Abstract available
    
    
    
97. MOUNTRIS KA, Visvikis D, Bert J
    DVH-Based Inverse Planning Using Monte Carlo Dosimetry for LDR Prostate Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2019;103:503-510.
    PubMed     Abstract available
    
    
    
98. HERRERA FG, Valerio M, Berthold D, Tawadros T, et al
    50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
    Int J Radiat Oncol Biol Phys. 2019;103:320-334.
    PubMed     Abstract available
    
    
    January 2019
99. GLICKSMAN R, Sanmamed N, Thoms J, Zlotta AR, et al
    A phase I pilot study of pre-operative radiotherapy for prostate cancer: Long-term toxicity and oncologic outcomes.
    Int J Radiat Oncol Biol Phys. 2019 Jan 6. pii: S0360-3016(19)30001.
    PubMed     Abstract available
    
    
    
100. ZELEFSKY MJ, Kollmeier M, McBride S, Varghese M, et al
     5-Year Outcomes of a Phase I Dose Escalation Study Using Stereotactic Body Radiosurgery for Patients with Low and Intermediate Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2019 Jan 3. pii: S0360-3016(18)34227.
     PubMed     Abstract available
     
     
     
101. ZUMSTEG ZS, Spratt DE
     Precision Medicine for Localized Prostate Cancer: Time to Move Beyond NCCN Risk Stratification?
     Int J Radiat Oncol Biol Phys. 2019;103:92-94.
     PubMed    
     
     
     
102. BERLIN A, Murgic J, Hosni A, Pintilie M, et al
     Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy.
     Int J Radiat Oncol Biol Phys. 2019;103:84-91.
     PubMed     Abstract available
     
     
     
103. SALDI S, Bellavita R, Lancellotta V, Palumbo I, et al
     Acute Toxicity Profiles of Hypofractionated Adjuvant and Salvage Radiation Therapy After Radical Prostatectomy: Results of a Prospective Study.
     Int J Radiat Oncol Biol Phys. 2019;103:105-111.
     PubMed     Abstract available
     
     
     December 2018
104. VAUGIER L, Palpacuer C, Rio E, Goineau A, et al
     Early toxicity of a phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer (OLIGOPELVIS GETUG P07).
     Int J Radiat Oncol Biol Phys. 2018 Dec 14. pii: S0360-3016(18)34186.
     PubMed     Abstract available
     
     
     
105. BRYANT AK, McKay RR, Kader AK, Parsons JK, et al
     Sub-castrate testosterone nadir and clinical outcomes in intermediate or high-risk localized prostate cancer.
     Int J Radiat Oncol Biol Phys. 2018 Dec 10. pii: S0360-3016(18)34080.
     PubMed     Abstract available
     
     
     
106. DEARNALEY D, Griffin CL, Lewis R, Mayles P, et al
     Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL).
     Int J Radiat Oncol Biol Phys. 2018 Dec 6. pii: S0360-3016(18)33854.
     PubMed     Abstract available
     
     
     November 2018
107. WORTEL RC, Oomen-de Hoop E, Heemsbergen WD, Pos FJ, et al
     Moderate hypofractionation in intermediate and high risk, localized prostate cancer: Health-related quality of life from the randomized, phase 3 HYPRO trial.
     Int J Radiat Oncol Biol Phys. 2018 Nov 17. pii: S0360-3016(18)34006.
     PubMed     Abstract available
     
     
     
108. ALAYED Y, Cheung P, Vesprini D, Liu S, et al
     SABR in high risk prostate cancer: outcomes from two prospective clinical trials with and without elective nodal irradiation.
     Int J Radiat Oncol Biol Phys. 2018 Nov 13. pii: S0360-3016(18)33997.
     PubMed     Abstract available
     
     
     
109. SPIEGEL DY, Hong JC, Oyekunle T, Waters L, et al
     A Nomogram for Testosterone Recovery Following Combined Androgen Deprivation and Radiation Therapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2018 Nov 9. pii: S0360-3016(18)33954.
     PubMed     Abstract available
     
     
     
110. SPRATT DE
     Evidence-based Risk Stratification to Guide Hormone Therapy Use With Salvage Radiation Therapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2018;102:556-560.
     PubMed    
     
     
     
111. MURGIC J, Morton G, Loblaw A, D'Alimonte L, et al
     Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial.
     Int J Radiat Oncol Biol Phys. 2018;102:561-567.
     PubMed     Abstract available
     
     
     October 2018
112. CARLES J, Gallardo E, Domenech M, Font A, et al
     Phase II randomized study of radiotherapy and three-year androgen deprivation with or without concurrent weekly docetaxel in high-risk localized prostate cancer patients.
     Int J Radiat Oncol Biol Phys. 2018 Oct 12. pii: S0360-3016(18)33856.
     PubMed     Abstract available
     
     
     
113. CROOK JM, Zhang P, Pisansky TM, Trabulsi EJ, et al
     A Prospective Phase II Trial of Trans-perineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiotherapy (NRG Oncology/RTOG -0526).
     Int J Radiat Oncol Biol Phys. 2018 Oct 9. pii: S0360-3016(18)33830.
     PubMed     Abstract available
     
     
     
114. MEIER RM, Bloch DA, Cotrutz C, Beckman AC, et al
     Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.
     Int J Radiat Oncol Biol Phys. 2018;102:296-303.
     PubMed     Abstract available
     
     
     September 2018
115. EVANS JD, Morris LK, Zhang H, Cao S, et al
     Prospective Immunophenotyping of CD8(+) T-cells and Associated Clinical Outcomes of Patients with Oligometastatic Prostate Cancer Treated with Metastasis-Directed SBRT.
     Int J Radiat Oncol Biol Phys. 2018 Sep 8. pii: S0360-3016(18)33725.
     PubMed     Abstract available
     
     
     
116. SOLDATOV A, von Klot CAJ, Walacides D, Derlin T, et al
     Patterns of progression after (68)Ga-PSMA-ligand PET/CT-guided radiotherapy for recurrent prostate cancer.
     Int J Radiat Oncol Biol Phys. 2018 Sep 7. pii: S0360-3016(18)33708.
     PubMed     Abstract available
     
     
     
117. LEE DJ, Barocas DA, Zhao Z, Huang LC, et al
     Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2018;102:116-126.
     PubMed     Abstract available
     
     
     August 2018
118. OLSSON CE, Jackson A, Deasy JO, Thor M, et al
     A systematic post-QUANTEC review of tolerance doses for late toxicity after prostate cancer radiotherapy.
     Int J Radiat Oncol Biol Phys. 2018 Aug 17. pii: S0360-3016(18)33546.
     PubMed     Abstract available
     
     
     
119. HOLMES JA, Anderson RF, Hoffman LG, Showalter TN, et al
     Cardiovascular Preventive Care and Coordination Of Care In Prostate Cancer Survivors: A Multi-Institutional Prospective Study.
     Int J Radiat Oncol Biol Phys. 2018 Aug 9. pii: S0360-3016(18)33519.
     PubMed     Abstract available
     
     
     
120. PEARLSTEIN KA, Basak R, Chen RC
     Comparative effectiveness of prostate cancer treatment options: limitations of retrospective analysis of cancer registry data.
     Int J Radiat Oncol Biol Phys. 2018 Aug 9. pii: S0360-3016(18)33529.
     PubMed     Abstract available
     
     
     
121. CARRARA M, Massari E, Cicchetti A, Giandini T, et al
     Development of a "ready to use" graphical tool based on artificial neural network classification: application for the prediction of late fecal incontinence after prostate cancer radiotherapy.
     Int J Radiat Oncol Biol Phys. 2018 Aug 6. pii: S0360-3016(18)33482.
     PubMed     Abstract available
     
     
     
122. ADAMS Q, Hopfensperger KM, Kim Y, Wu X, et al
     Effectiveness of Rotating Shield Brachytherapy for Prostate Cancer Dose Escalation and Urethral Sparing.
     Int J Radiat Oncol Biol Phys. 2018 Aug 6. pii: S0360-3016(18)33483.
     PubMed     Abstract available
     
     
     
123. NGUYEN PL
     The Long and Short of It: New Lessons on the Optimal Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer and Where We Need to Go From Here.
     Int J Radiat Oncol Biol Phys. 2018;101:1014-1017.
     PubMed    
     
     
     July 2018
124. DE CREVOISIER R, Bayar MA, Pommier P, Muracciole X, et al
     Daily versus weekly prostate cancer image-guided radiotherapy: Phase 3 multicenter randomized trial.
     Int J Radiat Oncol Biol Phys. 2018 Jul 30. pii: S0360-3016(18)33463.
     PubMed     Abstract available
     
     
     
125. MUSUNURU HB, D'Alimonte L, Davidson M, Ho L, et al
     Phase I/II Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients with High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life.
     Int J Radiat Oncol Biol Phys. 2018 Jul 30. pii: S0360-3016(18)33462.
     PubMed     Abstract available
     
     
     
126. EADE T, Choudhury A, Pollack A, Abramowitz M, et al
     Acute Epithelial Toxicity Is Prognostic for Improved Prostate Cancer Response to Radiation Therapy: A Retrospective, Multicenter, Cohort Study.
     Int J Radiat Oncol Biol Phys. 2018;101:957-963.
     PubMed     Abstract available
     
     
     
127. SPRATT DE
     Ki-67 Remains Solely a Prognostic Biomarker in Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2018;101:513-515.
     PubMed    
     
     
     June 2018
128. CICCHETTI A, Avuzzi B, Palorini F, Ballarini F, et al
     Predicting Late Fecal Incontinence Risk After Radiation Therapy for Prostate Cancer: New Insights From External Independent Validation.
     Int J Radiat Oncol Biol Phys. 2018 Jun 30. pii: S0360-3016(18)30806.
     PubMed     Abstract available
     
     
     
129. LUKKA HR, Pugh SL, Bruner DW, Bahary JP, et al
     Patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer.
     Int J Radiat Oncol Biol Phys. 2018 Jun 15. pii: S0360-3016(18)30961.
     PubMed     Abstract available
     
     
     May 2018
130. LEE S, Kerns S, Ostrer H, Rosenstein B, et al
     Machine Learning on a Genome-wide Association Study to Predict Late Genitourinary Toxicity After Prostate Radiation Therapy.
     Int J Radiat Oncol Biol Phys. 2018;101:128-135.
     PubMed     Abstract available
     
     
     April 2018
131. MCGARRY SD, Hurrell SL, Iczkowski KA, Hall W, et al
     Radio-pathomic Maps of Epithelium and Lumen Density Predict the Location of High-Grade Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2018 Apr 24. pii: S0360-3016(18)30701.
     PubMed     Abstract available
     
     
     
132. GOMEZ-ITURRIAGA A, Casquero F, Pijoan JI, Crook J, et al
     Pretreatment Multiparametric Magnetic Resonance Imaging Findings Are More Accurate Independent Predictors of Outcome Than Clinical Variables in Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2018 Apr 22. pii: S0360-3016(18)30696.
     PubMed     Abstract available
     
     
     
133. BRYANT AK, Kader AK, McKay RR, Einck JP, et al
     Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2018 Apr 17. pii: S0360-3016(18)30680.
     PubMed     Abstract available
     
     
     
134. WILSON JM, Dearnaley DP, Syndikus I, Khoo V, et al
     The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.
     Int J Radiat Oncol Biol Phys. 2018;100:1179-1189.
     PubMed     Abstract available
     
     
     
135. THARMALINGAM H, Choudhury A
     Relapsing Prostate Cancer: Castrate or Cure?
     Int J Radiat Oncol Biol Phys. 2018;100:1095-1096.
     PubMed    
     
     
     
136. ONG WL, Evans S, Millar J
     In Regard to Yang et al.
     Int J Radiat Oncol Biol Phys. 2018;100:1294-1295.
     PubMed    
     
     
     
137. SONG D
     Apply an Oligometastatic Paradigm for Nodal Recurrence.
     Int J Radiat Oncol Biol Phys. 2018;100:1098-1099.
     PubMed    
     
     
     
138. MENDIRATTA P, Garcia J
     Androgen Deprivation Fortified.
     Int J Radiat Oncol Biol Phys. 2018;100:1098.
     PubMed    
     
     
     
139. TRAN PT, Feng F, Ost P
     Live to SABR Another Day?
     Int J Radiat Oncol Biol Phys. 2018;100:1097.
     PubMed    
     
     
     March 2018
140. BRENNER DJ, Hall EJ
     Are We Now Able to Define Guidelines for Moderate Hypofractionation in Prostate Cancer Radiation Therapy?
     Int J Radiat Oncol Biol Phys. 2018;100:871-873.
     PubMed    
     
     
     
141. FONTEYNE V, Sarrazyn C, Swimberghe M, De Meerleer G, et al
     4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 Trial.
     Int J Radiat Oncol Biol Phys. 2018;100:866-870.
     PubMed     Abstract available
     
     
     
142. VOGELIUS IR, Bentzen SM
     Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials.
     Int J Radiat Oncol Biol Phys. 2018;100:858-865.
     PubMed     Abstract available
     
     
     
143. SANDLER HM
     Role of Overall Treatment Time in the Management of Prostate Cancer Patients: How to Manage Unscheduled Treatment Interruptions.
     Int J Radiat Oncol Biol Phys. 2018;100:841-842.
     PubMed    
     
     
     
144. MAINTA IC, Zilli T, Tille JC, De Perrot T, et al
     The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An (18)F-MISO PET-MRI Study.
     Int J Radiat Oncol Biol Phys. 2018 Mar 8. pii: S0360-3016(18)30476.
     PubMed     Abstract available
     
     
     
145. VALICENTI RK, Pugh SL, Trabulsi EJ, Sartor O, et al
     First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy.
     Int J Radiat Oncol Biol Phys. 2018;100:695-701.
     PubMed     Abstract available
     
     
     February 2018
146. CYSOUW M, Bouman-Wammes E, Hoekstra O, van den Eertwegh A, et al
     Prognostic Value of [(18)F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2018 Feb 13. pii: S0360-3016(18)30252.
     PubMed     Abstract available
     
     
     
147. TANDBERG DJ, Oyekunle T, Lee WR, Wu Y, et al
     Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens.
     Int J Radiat Oncol Biol Phys. 2018 Feb 8. pii: S0360-3016(18)30248.
     PubMed     Abstract available
     
     
     
148. KEALL PJ, Colvill E, O'Brien R, Caillet V, et al
     Electromagnetic-Guided MLC Tracking Radiation Therapy for Prostate Cancer Patients: Prospective Clinical Trial Results.
     Int J Radiat Oncol Biol Phys. 2018 Feb 6. pii: S0360-3016(18)30222.
     PubMed     Abstract available
     
     
     
149. AKSNESSAETHER BY, Solberg A, Klepp OH, Myklebust TA, et al
     Does Prophylactic Radiation Therapy to Avoid Gynecomastia in Patients With Prostate Cancer Increase the Risk of Breast Cancer?
     Int J Radiat Oncol Biol Phys. 2018 Feb 5. pii: S0360-3016(18)30220.
     PubMed     Abstract available
     
     
     
150. WILKINS AC, Gusterson B, Szijgyarto Z, Haviland J, et al
     Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2018 Feb 3. pii: S0360-3016(18)30186.
     PubMed     Abstract available
     
     
     
151. GRAFF P, Portalez D, Lusque A, Brun T, et al
     IDEAL 2a Phase II Study of Ultrafocal Brachytherapy for Low- and Intermediate-risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2018 Feb 2. pii: S0360-3016(18)30180.
     PubMed     Abstract available
     
     
     
152. DORTH JA, Lee WR, Chino J, Abouassaly R, et al
     Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2018;100:383-390.
     PubMed     Abstract available
     
     
     January 2018
153. DESS RT, Devasia TP, Aghdam N, Jackson WC, et al
     Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2018 Jan 31. pii: S0360-3016(18)30127.
     PubMed     Abstract available
     
     
     
154. YANG DD, Muralidhar V, Mahal BA, Nguyen PL, et al
     Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
     Int J Radiat Oncol Biol Phys. 2018;100:53-58.
     PubMed     Abstract available
     
     
     
155. ROMESSER PB, Pei X, Shi W, Zhang Z, et al
     Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
     Int J Radiat Oncol Biol Phys. 2018;100:59-67.
     PubMed     Abstract available
     
     
     
156. JOHNSTONE E, Wyatt JJ, Henry AM, Short SC, et al
     Systematic Review of Synthetic Computed Tomography Generation Methodologies for Use in Magnetic Resonance Imaging-Only Radiation Therapy.
     Int J Radiat Oncol Biol Phys. 2018;100:199-217.
     PubMed     Abstract available
     
     
     
157. QIN N, Shen C, Tsai MY, Pinto M, et al
     Full Monte Carlo-Based Biologic Treatment Plan Optimization System for Intensity Modulated Carbon Ion Therapy on Graphics Processing Unit.
     Int J Radiat Oncol Biol Phys. 2018;100:235-243.
     PubMed     Abstract available
     
     
     
158. CHI MS, Yang KL, Chang YC, Ko HL, et al
     Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial.
     Int J Radiat Oncol Biol Phys. 2018;100:78-87.
     PubMed     Abstract available
     
     
     December 2017
159. VIGNEAULT E, Martell K, Taussky D, Husain S, et al
     Does Seed Migration Increase the Risk of Second Malignancies in Prostate Cancer Patients Treated With Iodine-125 Loose Seeds Brachytherapy?
     Int J Radiat Oncol Biol Phys. 2017 Dec 28. pii: S0360-3016(17)34499.
     PubMed     Abstract available
     
     
     
160. MCCLELLAND S 3RD, Jaboin JJ, Mitin T
     Is Advocacy for Active Surveillance Over Definitive Intervention in Low-Risk Prostate Cancer Applicable to African American Patients?
     Int J Radiat Oncol Biol Phys. 2017;99:1076-1077.
     PubMed    
     
     
     
161. WORTEL RC, Heemsbergen WD, Smeenk RJ, Witte MG, et al
     Local Protocol Variations for Image Guided Radiation Therapy in the Multicenter Dutch Hypofractionation (HYPRO) Trial: Impact of Rectal Balloon and MRI Delineation on Anorectal Dose and Gastrointestinal Toxicity Levels.
     Int J Radiat Oncol Biol Phys. 2017;99:1243-1252.
     PubMed     Abstract available
     
     
     
162. WADDLE MR, Sio TT, Van Houten HK, Foote RL, et al
     Photon and Proton Radiation Therapy Utilization in a Population of More Than 100 Million Commercially Insured Patients.
     Int J Radiat Oncol Biol Phys. 2017;99:1078-1082.
     PubMed     Abstract available
     
     
     November 2017
163. YANG DD, Muralidhar V, Nguyen PL, Buzurovic I, et al
     Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2017;99:904-911.
     PubMed     Abstract available
     
     
     
164. KOONTZ BF
     Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer: The Hunt for the Silver Bullet.
     Int J Radiat Oncol Biol Phys. 2017;99:761-763.
     PubMed    
     
     
     
165. VAN DER VELDEN JM, Peters M, Verlaan JJ, Versteeg AL, et al
     Development and Internal Validation of a Clinical Risk Score to Predict Pain Response After Palliative Radiation Therapy in Patients With Bone Metastases.
     Int J Radiat Oncol Biol Phys. 2017;99:859-866.
     PubMed     Abstract available
     
     
     
166. LIM-REINDERS S, Keller BM, Al-Ward S, Sahgal A, et al
     Online Adaptive Radiation Therapy.
     Int J Radiat Oncol Biol Phys. 2017;99:994-1003.
     PubMed     Abstract available
     
     
     
167. BARADARAN-GHAHFAROKHI M, Amouheidari A, Shahbazi-Gahrouei D, Baradaran-Ghahfarokhi HR, et al
     Evaluation of the Effects of Prostate Radiation Therapy on Occludin Expression and Ultrasonography Characteristics of the Bladder.
     Int J Radiat Oncol Biol Phys. 2017;99:963-971.
     PubMed     Abstract available
     
     
     
168. MARTELL K, Husain S, Taussky D, Angyalfi S, et al
     Multicenter Evaluation of Biochemical Relapse-Free Survival Outcomes for Intraoperatively Planned Prostate Brachytherapy Using an Automated Delivery System.
     Int J Radiat Oncol Biol Phys. 2017;99:895-903.
     PubMed     Abstract available
     
     
     
169. GUPTA SK, Watson T, Denham J, Shakespeare TP, et al
     Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning.
     Int J Radiat Oncol Biol Phys. 2017;99:701-709.
     PubMed     Abstract available
     
     
     
170. DATTA NR, Stutz E, Rogers S, Bodis S, et al
     Conventional Versus Hypofractionated Radiation Therapy for Localized or Locally Advanced Prostate Cancer: A Systematic Review and Meta-analysis along with Therapeutic Implications.
     Int J Radiat Oncol Biol Phys. 2017;99:573-589.
     PubMed     Abstract available
     
     
     
171. CHOUDHURY A
     ProtecTing Low-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2017;99:515-517.
     PubMed    
     
     
     
172. BERLIN A, Ahmad AE, Chua MLK, Moraes FY, et al
     Curative Radiation Therapy at Time of Progression Under Active Surveillance Compared With Up-Front Radical Radiation Therapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2017 Nov 1. pii: S0360-3016(17)34048.
     PubMed     Abstract available
     
     
     October 2017
173. ADJEIWAAH M, Bylund M, Lundman JA, Karlsson CT, et al
     Quantifying the Effect of 3T Magnetic Resonance Imaging Residual System Distortions and Patient-Induced Susceptibility Distortions on Radiation Therapy Treatment Planning for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2017 Oct 20. pii: S0360-3016(17)34027.
     PubMed     Abstract available
     
     
     
174. FRANK SJ, Pugh TJ, Blanchard P, Mahmood U, et al
     Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes.
     Int J Radiat Oncol Biol Phys. 2017 Oct 12. pii: S0360-3016(17)33968.
     PubMed     Abstract available
     
     
     
175. ECHEVARRIA MI, Naghavi AO, Abuodeh YA, Ahmed KA, et al
     Low-dose-rate Brachytherapy for Prostate Cancer in Low-resource Settings.
     Int J Radiat Oncol Biol Phys. 2017;99:378-382.
     PubMed     Abstract available
     
     
     
176. PINKAWA M, Berneking V, Schlenter M, Krenkel B, et al
     Quality of Life After Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: 5-Year Results.
     Int J Radiat Oncol Biol Phys. 2017;99:374-377.
     PubMed     Abstract available
     
     
     September 2017
177. KEAM SP, Caramia F, Gamell C, Paul PJ, et al
     The Transcriptional Landscape of Radiation-Treated Human Prostate Cancer: Analysis of a Prospective Tissue Cohort.
     Int J Radiat Oncol Biol Phys. 2017 Sep 25. pii: S0360-3016(17)33937.
     PubMed     Abstract available
     
     
     
178. KERSHAW L, van Zadelhoff L, Heemsbergen W, Pos F, et al
     Image Guided Radiation Therapy Strategies for Pelvic Lymph Node Irradiation in High-Risk Prostate Cancer: Motion and Margins.
     Int J Radiat Oncol Biol Phys. 2017 Sep 8. pii: S0360-3016(17)33841.
     PubMed     Abstract available
     
     
     
179. PICKLES T, Tyldesley S, Hamm J, Virani SA, et al
     Brachytherapy for Intermediate-Risk Prostate Cancer, Androgen Deprivation, and the Risk of Death.
     Int J Radiat Oncol Biol Phys. 2017 Sep 4. pii: S0360-3016(17)33839.
     PubMed     Abstract available
     
     
     
180. DAYES IS, Parpia S, Gilbert J, Julian JA, et al
     Long-Term Results of a Randomized Trial Comparing Iridium Implant Plus External Beam Radiation Therapy With External Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate.
     Int J Radiat Oncol Biol Phys. 2017;99:90-93.
     PubMed     Abstract available
     
     
     
181. SUJENTHIRAN A, Nossiter J, Charman SC, Parry M, et al
     National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2017 Sep 1. pii: S0360-3016(17)33654.
     PubMed     Abstract available
     
     
     August 2017
182. AGGARWAL A, Lewis D, Sujenthiran A, Charman SC, et al
     Hospital Quality Factors Influencing the Mobility of Patients for Radical Prostate Cancer Radiation Therapy: A National Population-Based Study.
     Int J Radiat Oncol Biol Phys. 2017 Aug 24. pii: S0360-3016(17)33774.
     PubMed     Abstract available
     
     
     
183. REIS FERREIRA M, Khan A, Thomas K, Truelove L, et al
     Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2017 Aug 2. pii: S0360-3016(17)33655.
     PubMed     Abstract available
     
     
     
184. MALLA B, Zaugg K, Vassella E, Aebersold DM, et al
     Exosomes and Exosomal MicroRNAs in Prostate Cancer Radiation Therapy.
     Int J Radiat Oncol Biol Phys. 2017;98:982-995.
     PubMed     Abstract available
     
     
     
185. GLASER SM, Chen KS, Benoit RM, Smith RP, et al
     Long-Term Quality of Life in Prostate Cancer Patients Treated With Cesium-131.
     Int J Radiat Oncol Biol Phys. 2017;98:1053-1058.
     PubMed     Abstract available
     
     
     
186. WANG C, Kishan AU, Kamrava M, Steinberg ML, et al
     External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
     Int J Radiat Oncol Biol Phys. 2017;98:1045-1052.
     PubMed     Abstract available
     
     
     
187. BEN-JOSEF AM, Chen J, Wileyto P, Doucette A, et al
     Effect of Eischens Yoga During Radiation Therapy on Prostate Cancer Patient Symptoms and Quality of Life: A Randomized Phase II Trial.
     Int J Radiat Oncol Biol Phys. 2017;98:1036-1044.
     PubMed     Abstract available
     
     
     July 2017
188. FANG P, He W, Gomez DR, Hoffman KE, et al
     Influence of Age on Guideline-Concordant Cancer Care for Elderly Patients in the United States.
     Int J Radiat Oncol Biol Phys. 2017;98:748-757.
     PubMed     Abstract available
     
     
     
189. MIDDELBURG JG, Mast ME, de Kroon M, Jobsen JJ, et al
     Timed Get Up and Go Test and Geriatric 8 Scores and the Association With (Chemo-)Radiation Therapy Noncompliance and Acute Toxicity in Elderly Cancer Patients.
     Int J Radiat Oncol Biol Phys. 2017;98:843-849.
     PubMed     Abstract available
     
     
     
190. SONG YP, Ellis T, Walshaw R, Mbanu P, et al
     Comparing Clinical Outcomes for Radium-223: Do Older Patients Do Worse?
     Int J Radiat Oncol Biol Phys. 2017;98:955-957.
     PubMed     Abstract available
     
     
     
191. WAHL DR, Nguyen PL, Santiago M, Yousefi K, et al
     Pan-Cancer Analysis of Genomic Sequencing Among the Elderly.
     Int J Radiat Oncol Biol Phys. 2017;98:726-732.
     PubMed     Abstract available
     
     
     
192. MOROTE J, Tabernero AJ, Alvarez Ossorio JL, Ciria JP, et al
     Cognitive Function in Patients With Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter Study.
     Int J Radiat Oncol Biol Phys. 2017;98:590-594.
     PubMed     Abstract available
     
     
     
193. RODDA S, Morris WJ, Hamm J, Duncan G, et al
     ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2017;98:581-589.
     PubMed     Abstract available
     
     
     
194. CORKUM MT
     Prostate Cancer With Isolated Bony Metastasis: Sternal Struggle.
     Int J Radiat Oncol Biol Phys. 2017;98:492-493.
     PubMed    
     
     
     
195. SIVA S
     Prostate-Specific Membrane Antigen PET Before Aggressive Local Therapy to the Sternum.
     Int J Radiat Oncol Biol Phys. 2017;98:494-495.
     PubMed    
     
     
     June 2017
196. DADKHAH H, Hopfensperger KM, Kim Y, Wu X, et al
     Multisource Rotating Shield Brachytherapy Apparatus for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2017 Jun 20. pii: S0360-3016(17)31057.
     PubMed     Abstract available
     
     
     
197. SHENG Y, Li T, Lee WR, Yin FF, et al
     Exploring the Margin Recipe for Online Adaptive Radiation Therapy for Intermediate-Risk Prostate Cancer: An Intrafractional Seminal Vesicles Motion Analysis.
     Int J Radiat Oncol Biol Phys. 2017;98:473-480.
     PubMed     Abstract available
     
     
     
198. YANG DD, Muralidhar V, Mahal BA, Labe SA, et al
     National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2017;98:338-343.
     PubMed     Abstract available
     
     
     
199. O'CALLAGHAN ME, Raymond E, Campbell JM, Vincent AD, et al
     Patient-Reported Outcomes After Radiation Therapy in Men With Prostate Cancer: A Systematic Review of Prognostic Tool Accuracy and Validity.
     Int J Radiat Oncol Biol Phys. 2017;98:318-337.
     PubMed     Abstract available
     
     
     
200. LAWTON CAF, Lin X, Hanks GE, Lepor H, et al
     Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
     Int J Radiat Oncol Biol Phys. 2017;98:296-303.
     PubMed     Abstract available
     
     
     
201. SPRATT DE, Jagsi R
     Breast and Prostate Cancer: Lessons to Be Shared.
     Int J Radiat Oncol Biol Phys. 2017;98:263-268.
     PubMed    
     
     
     
202. CHARGARI C, Haie-Meder C, Guerin F, Minard-Colin V, et al
     Brachytherapy Combined With Surgery for Conservative Treatment of Children With Bladder Neck and/or Prostate Rhabdomyosarcoma.
     Int J Radiat Oncol Biol Phys. 2017;98:352-359.
     PubMed     Abstract available
     
     
     
203. GAY HA, Sanda MG, Liu J, Wu N, et al
     External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.
     Int J Radiat Oncol Biol Phys. 2017;98:304-317.
     PubMed     Abstract available
     
     
     May 2017
204. HAUCK CR, Ye H, Chen PY, Gustafson GS, et al
     Increasing Fractional Doses Increases the Probability of Benign PSA Bounce in Patients Undergoing Definitive HDR Brachytherapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2017;98:108-114.
     PubMed     Abstract available
     
     
     
205. GESTAUT MM, Cai W, Vyas S, Patel BJ, et al
     Low-Dose-Rate Brachytherapy Versus Cryotherapy in Low- and Intermediate-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2017;98:101-107.
     PubMed     Abstract available
     
     
     
206. CHEN WS, Townsend JP, Yu JB
     Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets.
     Int J Radiat Oncol Biol Phys. 2017;98:8-10.
     PubMed    
     
     
     April 2017
207. KANOUN S, Walker P, Vrigneaud JM, Depardon E, et al
     18F-Choline Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging for the Detection of Early Local Recurrence of Prostate Cancer Initially Treated by Radiation Therapy: Comparison With Systematic 3-Dimensional
     Int J Radiat Oncol Biol Phys. 2017;97:986-994.
     PubMed     Abstract available
     
     
     
208. CIEZKI JP, Weller M, Reddy CA, Kittel J, et al
     A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk
     Int J Radiat Oncol Biol Phys. 2017;97:962-975.
     PubMed     Abstract available
     
     
     
209. YOSHIOKA Y, Kotsuma T, Komiya A, Kariya S, et al
     Nationwide, Multicenter, Retrospective Study on High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2017;97:952-961.
     PubMed     Abstract available
     
     
     
210. BOSCO C, Garmo H, Adolfsson J, Stattin P, et al
     Prostate Cancer Radiation Therapy and Risk of Thromboembolic Events.
     Int J Radiat Oncol Biol Phys. 2017;97:1026-1031.
     PubMed     Abstract available
     
     
     
211. SCHILD MH, Schild SE, Wong WW, Vora SA, et al
     A Prospective Trial of Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for Prostate Cancer: Long-term Outcomes Compared With Standard Image Guided IMRT.
     Int J Radiat Oncol Biol Phys. 2017;97:1021-1025.
     PubMed     Abstract available
     
     
     
212. REED A, Valle LF, Shankavaram U, Krauze A, et al
     Effect of Prostate Magnetic Resonance Imaging/Ultrasound Fusion-guided Biopsy on Radiation Treatment Recommendations.
     Int J Radiat Oncol Biol Phys. 2017;97:947-951.
     PubMed     Abstract available
     
     
     
213. HAMSTRA DA, Mariados N, Sylvester J, Shah D, et al
     Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial.
     Int J Radiat Oncol Biol Phys. 2017;97:976-985.
     PubMed     Abstract available
     
     
     March 2017
214. SIMON A, Le Maitre A, Nassef M, Rigaud B, et al
     Is Dose Deformation-Invariance Hypothesis Verified in Prostate IGRT?
     Int J Radiat Oncol Biol Phys. 2017;97:830-838.
     PubMed     Abstract available
     
     
     
215. NICOLAE A, Morton G, Chung H, Loblaw A, et al
     Evaluation of a Machine-Learning Algorithm for Treatment Planning in Prostate Low-Dose-Rate Brachytherapy.
     Int J Radiat Oncol Biol Phys. 2017;97:822-829.
     PubMed     Abstract available
     
     
     
216. MIKSYS N, Vigneault E, Martin AG, Beaulieu L, et al
     Large-scale Retrospective Monte Carlo Dosimetric Study for Permanent Implant Prostate Brachytherapy.
     Int J Radiat Oncol Biol Phys. 2017;97:606-615.
     PubMed     Abstract available
     
     
     
217. PARKER WP, Evans JD, Stish BJ, Park SS, et al
     Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography.
     Int J Radiat Oncol Biol Phys. 2017;97:526-535.
     PubMed     Abstract available
     
     
     February 2017
218. YAHYA N, Ebert MA, House MJ, Kennedy A, et al
     Modeling Urinary Dysfunction After External Beam Radiation Therapy of the Prostate Using Bladder Dose-Surface Maps: Evidence of Spatially Variable Response of the Bladder Surface.
     Int J Radiat Oncol Biol Phys. 2017;97:420-426.
     PubMed     Abstract available
     
     
     
219. MISHRA MV, Aggarwal S, Bentzen SM, Knight N, et al
     Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials.
     Int J Radiat Oncol Biol Phys. 2017;97:228-235.
     PubMed     Abstract available
     
     
     
220. PISANSKY TM, Tendulkar RD
     In Reply to Ghadjar et al.
     Int J Radiat Oncol Biol Phys. 2017;97:439-440.
     PubMed    
     
     
     January 2017
221. RODDA S, Tyldesley S, Morris WJ, Keyes M, et al
     ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
     Int J Radiat Oncol Biol Phys. 2017 Jan 6. pii: S0360-3016(17)30008.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: